⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NAMS News
NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
NAMS
Form 8-K
sec.gov
NAMSW
NAMS
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
globenewswire.com
NAMS
Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco®
prnewswire.com
NAMS
Le Groupe Menarini et NewAmsterdam Pharma obtiennent l'autorisation de la Commission européenne pour Ubeslo® (obicetrapib en monothérapie) et Evlarco® (association à dose fixe d'obicetrapib et d'ézétimibe)
prnewswire.com
NAMS
Form 8-K
sec.gov
NAMS
NAMSW
Menarini Group und NewAmsterdam Pharma erhalten von der Europäischen Kommission die Zulassung für Ubeslo® (Obicetrapib als Monotherapie) und Evlarco® (Fixkombination aus Obicetrapib und Ezetimib)
prnewswire.com
NAMS
Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
prnewswire.com
NAMS
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
globenewswire.com
NAMS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
NAMS